The Role of <sup>18</sup>F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis

<div>Proportion of studies with low, high, or unclear risk of bias. Proportion of studies with low or unclear concerns regarding applicability.</div>

BioMed Research International

fig2

Figure 2

Figure 2: The Role of <sup>18</sup>F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis 

Figure 2 | The Role of 18F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis 